OverviewSuggest Edit

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients.
TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy-induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications.
TypePublic
Founded2010
HQWaltham, US
Websitetesarobio.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Sept 2017)446
Revenue (FY, 2017)$223.3 M(+399%)
Share Price (Jan 2019)$75

Key People/Management at TESARO

Mary Lynne Hedley

Mary Lynne Hedley

President, Chief Operating Officer
William Aitchison

William Aitchison

Senior Vice President, Technical Operations
Greg Covino

Greg Covino

Senior Vice President, Chief Accounting Officer
Allene Diaz

Allene Diaz

Senior Vice President, Global Commercial Development and Program Strategy
Martin Huber

Martin Huber

Senior Vice President, Chief Medical Officer
Jennifer Jackson

Jennifer Jackson

Senior Vice President, Global Regulatory Affairs & Quality Assurance
Show more

TESARO Office Locations

TESARO has offices in Waltham, Wien, Boulogne-Billancourt, München and in 4 other locations
Waltham, US (HQ)
1000 Winter St
Wien, AT
Fleischmarkt 1
Boulogne-Billancourt, FR
235 Avenue le Jour Se Lève
München, DE
Leopoldstraße 37a
Roma, IT
Via Vincenzo Bellini, 22
Madrid, ES
Camino de la Zarzuela, 19, 1ºC
Show all (8)

TESARO Financials and Metrics

TESARO Revenue

TESARO's revenue was reported to be $223.33 m in FY, 2017
USD

Revenue (Q3, 2018)

64.4m

Gross profit (Q3, 2018)

50.2m

Gross profit margin (Q3, 2018), %

77.9%

Net income (Q3, 2018)

(137.1m)

EBIT (Q3, 2018)

(138.2m)

Market capitalization (22-Jan-2019)

4.1b

Closing stock price (22-Jan-2019)

75.0

Cash (30-Sept-2018)

476.8m

EV

4.1b
TESARO's current market capitalization is $4.1 b.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

44.8m223.3m

Revenue growth, %

14040%

Cost of goods sold

268.0k1.3m41.1m

Gross profit

(268.0k)43.6m182.2m
Quarterly
USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

307.0k36.6m3.7m3.1m29.5m142.8m49.7m57.2m64.4m

Cost of goods sold

76.0k238.0k424.0k444.0k3.6m6.2m10.0m13.5m14.2m

Gross profit

231.0k36.3m3.3m2.6m25.8m136.6m39.7m43.7m50.2m

Gross profit Margin, %

75%99%89%86%88%96%80%76%78%
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

125.4m130.3m256.9m230.1m785.9m643.1m

Accounts Receivable

679.0k5.3m53.4m

Prepaid Expenses

1.2m4.0m1.7m4.6m33.5m

Inventories

1.1m14.7m57.9m
Quarterly
USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

68.9m138.6m198.6m178.1m156.4m180.3m151.1m295.9m399.1m354.4m302.5m314.5m320.2m647.3m672.2m507.9m521.3m499.0m575.1m476.8m

Accounts Receivable

1.1m1.1m510.0k3.2m6.1m23.1m27.7m44.2m35.7m31.4m

Prepaid Expenses

1.1m1.9m889.0k1.6m1.5m3.3m3.0m1.8m2.2m2.9m4.4m4.2m8.7m7.4m13.6m23.0m22.3m38.2m36.9m31.4m

Inventories

476.0k6.0m8.4m12.2m15.6m28.3m50.5m74.4m87.4m108.8m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(61.8m)(92.4m)(171.0m)(251.4m)(387.5m)(496.1m)

Depreciation and Amortization

64.0k179.0k349.0k9.5m

Inventories

(1.1m)(13.6m)(60.0m)

Accounts Payable

2.6m(1.3m)4.2m1.9m(2.8m)(1.0m)
USDY, 2018

EV/EBIT

-30 x

EV/CFO

-10.5 x

Debt/Equity

-3.8 x

Debt/Assets

0.7 x

Financial Leverage

-5.4 x
Show all financial metrics

TESARO Operating Metrics

FY, 2016

Countries

7

Patent Portfolios

3

Products

2
Show all operating metrics

TESARO Online and Social Media Presence

Embed Graph

TESARO News and Updates

TESARO BrandVoice: For Some With Ovarian Cancer, New Advancements Allay Unmet Need

Although cancer has at times dampened her spirits, Anna feels more at ease today knowing she has treatment options that aren’t restricted to her genetic makeup.

Lifshitz & Miller LLP Announces Investigation of Apptio, Inc., Black Box Corporation, CURO Group Holdings Corp., Finisar Corporation, Gaming Partners International Corporation, Resolute Energy Corporation, Tesaro, Inc., and Tribune Media Company

NEW YORK, Dec. 28, 2018 /PRNewswire/ -- Apptio, Inc. (APTI) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the sale of Apptio to Vista Equity Partners for $38.00 per share. If you are an Apptio investor, and would like additional...

GlaxoSmithKline's credit rating revised to negative at Moody's after Tesaro buyout deal

The outlook on GlaxoSmithKline PLC's credit rating was revised to negative from stable at Moody's Investors Service, which cited the drug giant's proposed acquisition of Tesaro Inc. . Moody's affirmed Glaxo's A2 long-term credit rating and its Prime-1 short-term rating. "We have changed [Glaxo's] o…

SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of Tesaro, Inc. - TSRO

NEW YORK, Dec. 4, 2018 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating the Board of Directors and Officers of Tesaro, Inc. ("Tesaro" or the ...

Thinking about buying stock in Atossa Genetics, Cronos Group, New Age Beverages Co, Tesaro Inc. or 22nd Century Group Inc.?

NEW YORK, Dec. 4, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATOS, CRON, NBEV, TSRO, and XXII. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ...
Show more

TESARO Blogs

Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer

Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer Brian.Hoenig@n… Tue, 03/19/2019 - 15:25 Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer …

TESARO Announces Data Presentations at the 2019 SGO Annual Meeting on Women’s Cancer

WALTHAM, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- TESARO, an oncology-focused business within GSK, today announced that data for dostarlimab (anti-PD-1 antibody, formerly TSR-042) and Zejula® (niraparib) will be presented at the 2019 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s

Actor Scott Foley and TESARO Team Up to Empower Ovarian Cancer Care Partners Through New Phase of Not on My Watch Movement

Actor Scott Foley and TESARO Team Up to Empower Ovarian Cancer Care Partners Through New Phase of Not on My Watch Movement Kerry.Russell@… Tue, 02/26/2019 - 07:30 Actor Scott Foley and TESARO Team Up to Empower Ovarian Cancer Care Partners Through New Phase of Not on My Watch Movement …

TESARO, Inc. Provides Notice of Fundamental Change, Conversion Rate Adjustment pursuant to Make-Whole Adjustment Event and Supplemental Indenture

WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- TESARO, Inc. (the “ Company ” or “ TESARO ”), an oncology-focused biopharmaceutical company, today announced that pursuant to the terms of the Indenture and the First Supplemental Indenture to the Indenture (collectively, the “ Indenture ”)

TESARO, Inc. Gives Notice of Anticipated Make-Whole Adjustment Event to Holders of Its Convertible Senior Notes

WALTHAM, Mass. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that, pursuant to the terms of the indenture (the “Indenture”) governing the terms of its 3.00% Convertible Senior notes due 2021 (the “Notes”), it

TESARO Frequently Asked Questions

  • When was TESARO founded?

    TESARO was founded in 2010.

  • Who are TESARO key executives?

    TESARO's key executives are Mary Lynne Hedley, William Aitchison and Greg Covino.

  • How many employees does TESARO have?

    TESARO has 446 employees.

  • What is TESARO revenue?

    Latest TESARO annual revenue is $223.3 m.

  • What is TESARO revenue per employee?

    Latest TESARO revenue per employee is $500.7 k.

  • Who are TESARO competitors?

    Competitors of TESARO include BeyondSpring, Northwest Biotherapeutics and Calithera Biosciences.

  • Where is TESARO headquarters?

    TESARO headquarters is located at 1000 Winter St, Waltham.

  • Where are TESARO offices?

    TESARO has offices in Waltham, Wien, Boulogne-Billancourt, München and in 4 other locations.

  • How many offices does TESARO have?

    TESARO has 8 offices.